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Abstract:  
During mammalian development, females inactivate randomly one of the two X chromosomes 
in a process called X-chromosome inactivation (XCI). This epigenetic event compensates the 
potential dosage differences of X-linked genes between sexes. The use of human pluripotent 
stem cells (hPSC) in regenerative applications and in-vitro modeling requires understanding of 
the XCI state and its impact upon generation of pluripotent cells. In this study, we investigated 
whether the XCI state of somatic cells had an influence on induced pluripoten stem cells 
(iPSC) reprogramming, through derivation of iPSC lines. We have generated ten iPSC from 
fibroblast of two healthy female donors (fibro ―S‖, fibro ―K‖) by lentiviral transduction of 
Yamanaka factors (OCT4, SOX2, KLF4 and c-MYC). The pluripotency state of the obtained 
iPSC lines was examined by immunoflurocence staining of protein surface markers: TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4, and RT-PCR analysis for pluripotency-associated genes 
expression:DNMT3B, GABRB3, GDF3, TDGF1 NANOG, POU5F1, and LIN28. Furthermore, we 
tested XCI patterns of iPSC lines and their fibroblast donors through DNA methylation 
analysis. This analysis was performed for theandrogen receptor (AR) gene using the 
methylation restriction enzyme HapII (HUMARA assay).Also, XCI patterns were analyzed 
for seven iPSC lines that were used in a different project and were previously derived from the 
same donor (fibro ―S‖).  
The ten iPSC lines ( S1,S2,S3,S4,S5,S6 from fibro S, and K1,K2,K3,K4 from fibro K ) 
showed positive results for pluripotency characterization, and expressed most of pluripotency 
genes and surface protein markers. 
The XCI results suggest that our iPSC lines were clonally derived from single fibroblast cells, 
since we observed non-random XCI pattern in all the lines that were derived. The fact that 5 
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out 6 S-lines and 4 out of 4 K-lines display skewing towards the same chromosome suggests 
that a particular X chromosome may confer a distinct advantage to these cells during cellular 
reprogramming or even during culture. Whether or not X chromosome reactivation occurs 
during reprogramming of these iPSC, it seems that the same X chromosome that was inactive 
in the paternal somatic cells is inactivated in the iPSC.  However, the other seven iPSC lines 
which were derived earlier in the lab showed random XCI. This is in contrast with the results 
obtained in the newly derived iPSC lines and raises questions. It is possible that reactivation 
happened during reprogramming followed by random inactivation, or these cells were not 
clonally derived.  
In conclusion, these results show a possible impact of XCI state upon iPSC reprogramming. 
To test this hypothesis, more experiments are needed with these iPSC lines and other lines 
derived from different donors.  
Keywords: XCI, Skewed XCI, human pluripotent stem cells, induced pluripotent stem cells, 
culture advantage, DNA methylation analysis, HUMARA assay. 
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Chapter One
Introduction 
_________________________________________________________________ 
 
1.1 X-Chromosome Inactivation:  
In mammals, sex is determined by pair of sex chromosomes (X and Y), with males it being 
(XY) and in females (XX). This induces an imbalance between the X-linked genes between 
the sexes. In order to compensate this dosage differences, X-Chromosome Inactivation (XCI) 
has occurred in females. XCI is an epigenetic process by which most of the genes on one of 
the X-chromosomes in female cells are silenced and usually occurs during the late blastocyst 
stage of the embryo (Lyon, 1961). XCI results in a single transcriptionally active X 
chromosome in female cells, thus comparable to male cells. Selection of which X 
chromosome becomes inactivated is entirely random, that half of the cells inactivate the 
maternally inherited X chromosome and the other half the paternal X. However, once the 
choice has been made in a particular cell, it is stably propagated to all of its daughter cells. 
 
1.2 Mechanism of XCI : 
The process of XCI involves four steps that are regulated in a developmental manner: counting 
the number of X chromosomes, choosing which X chromosome to be inactivated, initiation of 
silencing the selected chromosome, and maintenance of stable repression of the inactive X 
(Xi) (Disteche & Berletch, 2015). Initiation is established by the long non-coding RNA X 
inactive specific transcript (XIST), which is transcribed from the chromosome that will be 
inactivated. XIST coats the areas where it is actively transcribed along this chromosome, and 
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forms a ―cloud‖ by binding these areas.  The covered areas lose RNA polymerase II, initiation 
factors, and other components that are necessary for transcription. However, there are regions 
on the inactivated X chromosome that sustain active transcription, also called ―escape‖ 
inactivation, by looping out of the chromosomal territory covered by XIST (Briggs & Pera, 
2014). Apart from XCI maintenance, all of XCI steps are orchestrated by the X-inactivation 
center (XIC).As the transition from initiation to maintenance occurs, the inactivation status 
become irreversible (Wutz, 2011). The maintenance phase involves a number of epigenetic 
processes such as alteration of DNA methylation and histone modification for Xi .The DNA 
methylation of CpG islands performed by the methylases DNMT3A/B and maintained by 
DNMT1. One example of histone modification is the accumulation of  histone 3 lysine 27 
trimethylation (H3K27me3) that silences transcription by the aid of Polycomb group (PcG) 
complex, which is a protein complex containing Ezh2 (enhancer of zeste homolog 2) and Eed 
(polycomb protein Eed). This complex is attracted by XIST accumulation on the Xi. The 
repression occurs when Ezh2 converts H3K27me2 (histone H3 lysine 27 dimethylation) to 
H3K27me3 (histone H3 lysine 27 trimethylation), a repressive histone mark. Another 
examples of histone modifications, is the loss of the active histone marks like histone H3 
lysine 4 methylation (H3K4me) and  H3 lysine 9 acetylation (H3K9ac), and thereplacement of 
histone H2A by macrohistone H2A (figure 1.1). All of these Xi characterizations lead to a 
strong condensation of the chromatin into a perinuclear structure, also known as the Barr 
body, ensuring long-term transcriptional silencing (Disteche & Berletch, 2015) (M Geens et 
al., 2016).  
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1.3 Skewing of X-Chromosome inactivation : 
Although the choice of which of the two X chromosomes is inactivated is entirely random, not 
all women have a 50:50 ratio of cells with one or the other X chromosome active. This case of 
non-random inactivation is called ―skewing‖. Skewing of X chromosome inactivation is 
defined as a deviation of  ≥25% from the balanced (50:50) inactivation of each parental X 
chromosome, in at least 75% of the female cells (Pomp et al., 2011). It has been shown to 
occur in X-linked diseases, but also in 10% of healthy females, mainly in tissues with high 
proliferation, such as the hematopoietic cells. There are different mechanisms that may lead to 
a non-random X-chromosome state such as: genetics factors or mutations, aging 
,chromosomal rearrangements, and stochastic effects (Van den Veyver, 2001). Skewed XCI 
has also been linked to several pathologies such as intellectual disability, autoimmune 
diseases, such as autoimmune thyroid diseases (AITD), rheumatoid arthritis, and scleroderma. 
Also, aberrant XCI has been well documented in cancer but most data are only correlational 
(Mieke Geens & Chuva De Sousa Lopes, 2017). Consequently, determining the XCI states can 
be used as an indication of the presence of the diseases. 
Figure 1.1 :Main molecular characteristics distinguish between active X chromosome (Xa) and 
inactive X chromosome (Xi) . (Mieke Geens & Chuva De Sousa Lopes, 2017) 
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1.4 Stem cell potency : 
Stem cells are undifferentiated cells found in embryos and adults, they have the ability to give 
rise to differentiated cells which are the building blocks of tissues and organs (Kolios & 
Moodley, 2013). Depending on the differentiation potency, stem cells are classified into 
different categories: totipotent, pluripotent, multipotent, and oligopotent stem cells 
(Figure1.2). Totipotent cells are the most undifferentiated cells found in early development 
that can produce all the differentiated cells in an organism. A zygote formed at egg 
fertilization and the cells that result from the first two divisions are totipotent cells, as they 
differentiate into both embryonic and extraembryonic tissues, forming the embryo and 
placenta (Mitalipov & Wolf, 2009). 
Pluripotent stem cells defined as cells have the potential to differentiate into any cell types that 
arise from the three germ layers: ectoderm, endoderm, and mesoderm. Embryonic stem cells 
(ESC) are pluripotent cells were derived from inner cell mass of the blastocyst. Recently, 
pluripotent cells were generated by reprogramming of somatic cells, which defined as the 
reversal of the differentiation state of a mature cell to one that is characteristic of the 
undifferentiated embryonic state (Hochedlinger & Jaenisch, 2006). These generated cells 
called induced pluripotent stem cells (iPSC) had been derived by introducing four 
transcription factors (OCT4, SOX2, KLF4, and c-MYC) (Takahashi & Yamanaka, 2006).  
Multipotent cells are derived from pluripotent cells and capable of differentiating into some 
cell types derived from a single germ layer, such as mesenchymal stem cells which can 
differentiate into mesoderm-derived tissue such as adipose tissue, bone, cartilage, and muscle 
(Kolios & Moodley, 2013). Oligopotent or unipotent cells are able to form a few lineages, in 
oligopotent cells, or only one lineage (unipotent cells) within a specific tissue. Hematopoietic 
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stem cells are an example of oligopotent cells, they can differentiate into both myeloid and 
lymphoid lineages (Marone et al., 2002). 
 
 
 
 
1.5 Human Pluripotent Stem Cells (hPSC) as disease cellular models:  
Human pluripotent stem cells (hPSC), which include human embryonic stem cells (hESC) and 
human induced pluripotent stem cells (hiPSC), can self-renew indefinitely in culture and had 
the ability to become almost any cell type in the human body. Therefore, hPSC is used for cell 
replacement therapy and cellular modeling for human diseases and development. 
Understanding human development and the diseases caused by developmental and genetic 
defects, is one of the major challenges in biology. Much of our knowledge about human 
development has been extrapolated from studies of animal model organisms, since we cannot 
study human development in the same way we do when experimenting on a mouse or fruit fly. 
These models have produced key insights into the general principles of human development, 
disease mechanisms, as well as into the genes and signaling pathways that control specific 
aspects of cell fate specification and tissue morphogenesis (Zhu & Huangfu, 2013). Despite 
Figure 1.2: Classification of stem cells on the basis of potency into totipotent, pluripotent, 
multipotent , oligopotent and unipotent cells  (Mitalipov & Wolf, 2009).  
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these benefits, there are notable limitations of using animal models.  First, animal models do 
not accurately mimic the disease in human cells, as a result of species-specific differences 
between the animal system and that in humans. Another limitation rises from the genomic 
variation of the human and murine models; since around 1% of human genes have no 
identifiable mouse homologs (Consortium, 2001). Also, many genetic variants associated with 
human disease fall in the non-coding regions that show relatively little conservation, raising 
the possibility to get different phenotypes of human disease if we used animal variants. 
Furthermore, the majority of drugs that are effective in mice have failed in human clinical 
trials. Moreover, generating and breeding transgenic animals is expensive and time consuming 
(Merkle & Eggan, 2013). 
 
 Using hPSC is an essential complement with animal models to overcome these limitations. 
The potential of hPSC to differentiate to each cell type and its self-renewal capacity with 
rapid, cost-effective in-vitro culture offers an attractive window to understand human normal 
and abnormal development or pathogenesis of human diseases. Modeling human diseases ‗‗in 
a dish‖ started with hESC ; Thomson and colleagues derived hESC lines by culturing human 
blastocysts in a cocktail of growth factors and supporting mouse feeder cells (Thomson et al., 
1998). By Performing preimplantation genetic diagnosis (PGD) on embryos, one of the 
methods that used to predefine gene mutations, researcher were able to derive ‗‗disease-
specific‘‘ hESC from the identified genetic disorders such as for cystic fibrosis, Huntington‘s 
disease, and Fragile X syndrome. However, PGD embryos are available only for a limited 
number of human diseases. The forward genetic approach have also been utilized with hESC, 
by generating mutation in genomic loci with a specific disease at hESC, followed by the 
identification of a disease phenotype in hESC or their derivatives. This approach is limited to 
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the inefficient methods to genetically modify hESC. Neither all diseases are genetically known  
nor disease phenotype could be screened in hESC (Saha & Jaenisch, 2009). 
 
In a more recent breakthrough, reprogramming of mouse adult cells through viral transduction 
of four transcription factors (OCT4, SOX2, KLF4, and c-MYC) to produce induced 
pluripotent stem cells (iPSC) was reported by Yamanaka and colleagues in 2006. One year 
after, they generated human iPSC from human fibroblasts (Takahashi et al., 2007). Using this 
combination of Yamanka transcription factors is necessary and sufficient to return terminally 
differentiated cells to a pluripotent state. These iPSC are capable of generating tissues of all 
three germ layers, similar to the capacity of human embryonic stem cells (hESC). This 
techniques has also been applied to blood or skin samples harvested from patients diagnosed 
with specific diseases; allowing researchers to study the roles of a specific gene in 
developmental cell fate decisions and the physiological functions of disease-relevant cells 
(Saha & Jaenisch, 2009). 
Generation of ―Disease-specific‖ hiPSC lines from patients with many types of diseases could 
provide immune-matched supply of pluripotent cells,  that can be used in multipurpose 
research and clinical applications. ―Disease-specific‖ iPSC have been generated for various 
diseases; hematopoietic, hepatic ,endothelial, neurological, and cardiovascular diseases and 
the number  is  increasing, reflecting their growing utility as models for studying disease 
development, as well as platforms of drug screening and toxicity testing to investigate 
therapeutic agents (Ebert, Liang, & Wu, 2012). Furthermore, this approach of iPSC can be 
used to generate therapeutic cells for replacement therapy that may avoid immune rejection in 
the transplant recipient, since it can be generated directly from the patient.  
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1.6 Characterization of iPSC :  
As iPSC are very similar to hESC, the criteria used to characterize iPSC are very close to 
which employed to ESC research. Initially, the morphology of iPSC under microscope, is the 
first character used to identify potential iPSC. iPSC form-colonies of compact cells exhibiting 
a high nucleus to cytoplasmic ratio with a round tight shape and smooth borders. Moreover, 
iPSC and ESC have comparable growth rate, elevated telomerase and alkaline phosphatase 
activities. In addition, iPSC express specific cell surface proteins such as stage-specific 
embryonic antigen (SSEA)-3, SSEA-4, TRA-1-60, TRA-1-81, and pluripotency markers 
as:NANOG, OCT3/4, TDGF1, DNMT3B, GDF3, GABRB3, and LIN28. Gene expression of 
pluripotency markers is very essential to identify the plurioptent state of cells, since the 
clonality of iPS maybe different among the cells even if they are generated under identical 
conditions. This might because the cells are at different stages of reprogramming, or 
incomplete reprogramming that may render them to differintation with increased potential to 
teratomas formation (Ng & Choo, 2010). Masaki and colleagues observed that even alkaline 
phosphatase (ALP)- positive colonies can be categorized into 40 groups based on the gene 
expression pattern of 8 marker genes: NANOG, TDGF1, DNMT3B, ZFP42, FOXD3, GDF3, 
CYP26A1 and TERT, indicating the importance of characterization of endogenous 
pluripotency gene markers (Masaki et al., 2008). In table 1.1 we summarize the markers that 
we used in our work. 
 
As there is a difference between iPS and ES cells according to the reprogramming in iPSC, 
monitoring karyotype stability during culture is also needed for extended culture of both iPSC 
and human ES cells. Moreover, methylation status and differentiation into somatic cell types 
in vitro and in vivo are useful for testing stem cell pluripotency. 
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Table 1.1 List of genes and antigen markers used for iPSC pluripotency characterization in 
our work, and their role of function from literature and NCBI website.  
 
Marker  Type Role of function 
NANOG Gene/ antigen Establishment of pluripotency, resisting 
differentiation 
OCT 3/4 Gene/ antigen Essential for generation iPSC , maintain 
pluripotency  
SSEA 3/4 Antigen Stage-specific embryonic antigen, cell surface 
glycolipid 
TRA-1-60 Antigen  Stem cell surface keratan sulfate antigen epitope 
TRA-1-81 Antigen Stem cell surface keratan sulfate antigen epitope 
LIN28  Gene  Regulator of genes involved in developmental 
timing and self-renewal in embryonic stem cells 
DNMT3B Gene DNA methyltransferase 3 beta, play role in 
DNA methylation that is important for human 
development, imprinting, X chromosome 
inactivation 
GDF3 Gene Growth differentiation factor 3, encodes protein 
plays a role ocular and skeletal development.  
GABRB3 Gene  Gamma-aminobutyric acid type A receptor beta3 
subunit, encodes a member of the ligand-gated 
ionic channel family. 
TDGF1 Gene  Teratocarcinoma-derived growth factor 1, 
encoded proteins that play an essential role in 
embryonic development and tumor growth. 
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1.7 XCI in hPSC and hiPSC :  
Human pluripotent stem cells are classified into three classes according to their X 
chromosome state (Figure 1.3). Class I cells contain two active X chromosomes (XaXa) in the 
undifferentiated state and are considered closest to ground state pluripotency. Upon placing 
class I cells under differentiation conditions, XIST transcription initiates from the prospective 
Xi and random XCI begins. Class II cells have already initiated XCI (XaXi) and express XIST 
RNA even in the undifferentiated state. Finally, class III cells still retain XCI but have lost 
XIST expression, show accumulation of repressive histone modifications and often also XCI-
specific DNA methylation. This occurs regardless of whether they are growing in  
undifferentiated or differentiated conditions (Lessing & Lee, 2013). Class I is rare in humans, 
class II, III are more likely to happen. 
 
 
 
Studying the XCI state in hPSC has gained enormous interest and importance in disease 
modeling, as XCI markers have provided one of the few readouts of the pluripotent state.  
Upon the discovery of iPSC, a new subfield of characterization of XCI emerged. In mouse 
iPSC, it has been shown that reactivation happens during reprogramming. However, the X 
chromosome states during reprogramming of human iPSC is contradictory and complex. Some 
Figure 1.3: Classification of human pluripotent stem cells (hPSC) according to XCI state (Lessing & 
Lee, 2013) 
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groups such as Marchetto et al., reported reactivation of the X chromosome (XaXa) in iPSC 
colonies made from female Rette syndrome patients (Marchetto et al., 2010). On the other 
hand, Tchieu et al.showed that the X chromosome remains inactive (XaXi) and X 
chromosome reactivation never happens (Tchieu et al., 2010). They also obtained clonal 
hiPSC population exhibiting XCI. It is worth noting here that Lessing et al have summarized 
XCI status of hiPSCs from multiple labs (Lessing & Lee, 2013).  
 
There are reports regarding the variability in XCI of the same reprogrammed colony states. 
Bruck et al. reported that a single clone may contain cells of different states, Indicating that the 
variability is based on biological factors, not methodology. Also, they proposed a model of the 
dynamics of XCI in pluripotent stem cells (Bruck & Benvenisty, 2011). These differences 
raise questions about the stability of hiPSC cells and their impact on clinical trials, raising the 
need for careful characterization of their properties. In contrast, recent work of Tomoda and 
Yamanka et al. studied the effect of culture conditions and derivation on the epigenetic 
features of X chromosome in hiPSC. They used SNL feeders, which are immortalized mouse 
embryonic fibroblasts (MEF) that produce high levels of leukemia inhibitory factor (LIF), to 
derive and maintain hiPSC. They reported that the Xi of donor fibroblast was frequently 
reactivated (Xa/Xa) upon early passage on SNL, compared to non-frequent production of 
Xa/Xa when non-SNL feeders were used. Therefore, choosing the desired pattern Xa/Xi or 
Xa/Xa for the derived hiPSC is possible and could be useful in disease modeling and clinical 
applications (Tomoda et al., 2012). 
 
In order to determine whether a preferential XCI exists in hPSCs and whether the XCI pattern 
changes during long-term culture or upon differentiation, Geens et al.,  investigated the XCI 
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state in different female hPSC lines: two hiPSC and 21 hESC lines. The results shows that 
hPSC rapidly lose XCI marks during culture and become XIST-independent XCI state with 
loss of repressive histone modifications and often erosion of methylation. Also, they reported 
high incidence of non-random XCI related methylation pattern. This skewing of XCI pattern is 
independent from the origin of the X chromosome from paternal or maternal and is not 
occurring as passenger event, as chromosome aberration lead to culture take over. Most 
probably, XCI skewing driven by specific X-linked allele, that is activated or repressed, 
confers growth advantage to the cells (M Geens et al., 2016).It is also worth noting Pomp et al. 
study that proposed the cause of XCI skewing in hiPSC. They found that all iPSC colonies, 
which were derived from the same fibroblasts, contain the same inactive X. This skewed 
choice may be due to more efficient reprogramming of the donor fibroblast in which the 
dominant X was active. Notably,the skewing can be alleviated by introducing telomerase 
activity to these cell cultures (Pomp, Dreesen et al., 2011).  
 
XCI skewing in hiPSC have implications for using of female hiPSCs in clinical applications 
and disease modeling, especially for X-linked disease. Investigate the XCI state in hiPSC and 
whether it is compatible with the desired application, is an essential step before using it.   
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1.8 Aim Of The Study: 
From the literature, it seems that the XCI status may have a direct impact on the potential to 
generate hPSC and on their pluripotent status in vitro. The fact that most several labs report a 
very fast skewing of XCI patterns suggests that the presence and activity of specific X-linked 
alleles may directly confer a culture advantage (or disadvantage) to the cells. We would like to 
further investigate whether this can be true. A nice set-up would be to perform competition 
experiments with sublines of the same hESC line, but displaying an opposite skewed XCI 
pattern. However, all the hESC lines available in our lab already displayed a completely 
skewed XCI pattern, which did not allow us to derive clonal sublines with opposite XCI 
patterns. Therefore, we have worked on generating iPSC from fibroblast of healthy human 
females, to investigate if X chromosome inactivation status influences the efficiency of hiPSC 
reprogramming by studying XCI methylation related patterns in the derived iPSC lines. 
 
1.9 Objectives : 
1. To generate iPSC from two healthy female fibroblast by lentiviral transduction of                                       
Yamanaka factors (OCT4, SOX2, KLF4 and c-MYC). 
2. To characterize the pluripotency state in the derived iPSC lines by performing 
immunoflurocence staining for surface protein markers (TRA-1-81, TRA-1-60, SSEA3 
and SSEA4) and gene expression by RT-PCR for pluripotency marker genes 
(DNMT3B, GABRB3, GDF3, TDGF1, LIN28, NANOG, and OCT4). 
3. To investigate the XCI state of the derived iPSC by studying the methylation state of 
the X-chromosome using HUMARA assay. 
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1.10 Significance of The Study:  
Studying the XCI state in female hPSC is one of the major epigenetic factors that should be 
examined before any clinical applications. According to observing early skewing XCI in 
female hPSC, this study emphasizes the possibility of the presence of an X-linked event that 
gives cells with a specific XCI pattern a culture advantage over other cells and recommends 
further  research to prove this hypothesis.  
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Chapter Two 
 Materials and Methods 
 
2.1 Generation of human induced pluripotent stem cells (hiPSC):  
Two fibroblast lines (fibro ―S‖, fibro―K‖) from human healthy females were used for human 
iPSC derivation using lentiviral transduction with thpRRL.PPT.SF.hOKSM.idTomato.preFRT 
vector which contains the four Yamanaka factors: C-MYC, KLF4, SOX2 and POU5F1. 
Fibroblasts, which were derived from skin biopsies, were thawed and grown  in mouse 
embryonic fibroblast (MEF) medium consisting of DMEM (Thermo Fisher Scientific), 
supplemented with 20% heat inactivated fetal bovine serum (Thermo Fisher Scientific), 2 mM 
L-glutamine (Thermo Fisher Scientific) and 100 U/ml Pen/Strep (Thermo Fisher Scientific). 
One day before transduction, fibroblasts were plated in a 6-well plate at a density of 2.5 ×104 
cells/cm
2
. The transduction mix  which consists of 1×105 virus particles per well and 
protamine sulfate (10 µg/ml final concentration) was prepared and incubated for 15 minutes at 
room temperature (RT). Two ml of the mix was added per well and the cells were incubated at 
37
o
C, 5% CO2 for 24 hours. In the following days, the cells were washed three times with 
warm PBS and MEF medium was changed daily. Cells were passaged to coated dishes with 
Laminin (LN521) in Nutristem (NS) medium one week after plating. Single iPSC colonies 
were isolated based on ESC-like morphology. Six colonies from ―S‖ fibro line and 4 colonies 
from ―K‖ fibro line were mechanically isolated and further cultured on LN521-coated 24-well 
plates in NS medium, afterwards each isolated colony grew into an iPS cell line. Once the 
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cultures were confluent, they were passaged using TrpLE
TM 
Express (Thermo Fisher 
Scientific) in ratios ranging from 1:10 to 1:50.  
 
2.2 Immunofluorescence Staining:  
2.2.1 Fixation:  
Cultured iPSC lines on LN521 coated 4-well plates, were first washed twice with PBS for five 
minutes to each. Fixation was performed with 3.7% paraformaldehyde (PFA) (Sigma-aldrich) 
in PBS for 15 minutes at RT. After that, the plates were washed again as above. The fixed 
cells were stored in PBS at +4 °C.  
2.2.2 Staining (immunofluorescence): 
Before adding primary antibodies, cells were permeabilized with 0.1% Triton X-100 in PBS. 
Plates were incubated for 10 minutes, then washed three times 10 minutes with PBS. Blocking 
solution (3% of Bovin serum albumin (BSA) in PBS) was used to reduce non-specific 
antibody binding, therefore, 500µL of the solution was added to the wells and incubated for 
one hour at room temperature.  
Four primary antibodies (TRA-1-60, TRA-1-81, SSEA, SSEA4) were used to detect surface 
antigens. For antigen-antibody binding detection, secondary antibodies with fluorescent dye 
were added specifically to each primary antibody. In table 2.1 & 2.2, are listed the names of 
the primary and secondary antibodies used, with their dilution ratio. 
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 Table 2.1 List of primary antibodies:  
Primary Antibodies (against human protein)  Dilution ratio   Reference number & company  
TRA-1-81 mouse IgM   1:100  MAB 4381, Merck 
SSEA3 rat IgM   1:50  MAB 4303, Merck 
SSEA4 mouse IgG  1:100  MAB 4304, Merck 
TRA-1-60 mouse IgM  1:100   MAB 4360, Merck 
 
Table 2.2 List of secondary antibodies:  
 
After preparing the diluted primary antibodies, 300µL of each specific antibody was added to 
each well of the cells. The plates were wrapped with parafilm and kept overnight at 4
o
C.  
The next day, the primary antibodies were removed and the wells were washed with PBS three 
times. Then, 300 µL of the diluted secondary antibodies were added to the wells, based on 
which primary antibody was there. The plates were covered with aluminum foil to avoid the 
light and incubated at room temperature for two hours. After removing the secondary 
antibodies, the wells were washed three times with PBS. 300 µL of Hoechst 33342 (H3570, 
Thermo fisher Scientific), a nuclear stain, were added to each well and incubated for 10 to 15 
minutes in dark at room temperature. This stain was diluted 1:2000 with PBS before adding. 
After removal of Hoechst and washing with PBS, one drop of prolong Gold Anti-fade reagent 
(Thermo Fisher Scientific) was added to each well and covered with coverslip. The plates 
Secondary Antibodies   Dilution ratio Reference number & company  
Alexa 488 goat anti-mouse IgM   1:200 A21042, Thermo Fisher Scientific 
Alexa 488 goat anti-rat IgM  1:200 A-21212, Thermo Fisher Scientific  
Alexa 488 goat anti-mouse IgG 1:200 A11029, Thermo fisher Scientific  
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were kept in the fridge at 4
o
C, protected from the light. The stained cells were analyzed using 
the IX-81 fluorescent microscope (Olympus) with Cell^F software (Olympus). 
 
2.3 Gene expression for pluripotency markers:  
2.3.1 Pellet collection: 
Cell pellets from hiPSC and fibroblast lines were needed for molecular analysis. As the cells 
appeared confluent under the microscope, it was ready for passage and pellet collection. First, 
the cells were incubated with TrypLE
TM
 (Thermo Fisher Scientific) for 5 minutes, then diluted 
with PBS. The deattached cells were collected for centrifugation at 1000 rpm for 5 minutes. 
The supernatant, that appeared after centrifugation, was aspirated and the pellets resuspended 
in PBS for washing. Then, the cells were centrifuged again and the supernatant was discarded. 
The pellet tubes were stored at -80
o
C.   
2.3.2 RNA extraction with spin column method:  
RNA extraction from cell pellets was carried out using RNeasy Mini Kit, (QIAGEN) using the 
manufacturer‘s protocol. In brief, the cells were disrupted by adding lysis buffer RLT, that the 
volume of the buffer is selected according to number of pelleted cells. The lysate was passed 
through needle syringe to be homogenized, then an equal volume of 70% ethanol was added to 
the homogenized lysate. The sample was transferred to a spin column and centrifuged at 
10,000 rpm for 30 seconds. After a first washing step with 700 µl washing buffer RW1, 
DNase treatment was performed. The DNase mix, which consists of 10 µl DNase stock 
solution with 70µl RDD buffer, was directly added to the column membrane and incubated for 
15 minutes at benchtop. After that, the sample was washed again in 350 µl RW1 twice. 
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Finally, RNase-free water was added directly to the spin column membrane and RNA was 
eluted by spinning. The obtained RNA was stored at -80
o
C.  
2.3.3 Complementary DNA (cDNA) transcription: 
First-strand cDNA synthesis was performed using First-Strand cDNA Synthesis Kit, (GE 
Healthcare). 8µl of RNA solution was incubated at 65
o
C for 10 minutes. The reaction mix, 
which consists of 5µl bulk first-strand cDNA reaction mix, 1 µl primer, 1µl DTT solution, was 
prepared for each sample. Then, the mix was added to the RNA solution and the tubes were 
incubated at 37
o
C for 1 hour. The completed first-strand cDNA reaction product was ready 
and it was stored at 4
o
C.  
2.3.4 Gene expression by RT-PCR:  
The ten derived iPSC lines were analyzed for gene expression of pluripotency markers 
(DNMT3B, GABRB3, GDF3, LIN28, NANOG, POU5F1 and TDGF1) by qRT-PCR (Viia 7 
thermocycler, ViiA 7 software version 1.2; Thermo Fisher Scientific). GUSB and UBC were 
used as housekeeping genes for the reactions. The two fibroblast cultures from which the 
hiPSC were derived, were used as negative control. Reactions were performed using 
TaqMan® Fast Advanced Master Mix (Thermo Fisher Scientific) with 5ng/µL of cDNA from 
the cells (8 µl of  1300 ng /cDNA input per well). Assays for GABRB3, TDGF1, GDF3, 
DNMT3B and GUSB were performed according to published protocols (Supplementary Table 
1), whilst for all other genes, primers and probes were designed in-house (Supplementary 
Table 2). Amplification conditions  were the following: 20 seconds at 95°C and 40 cycles of 1 
second at 95°C and 20 seconds at 60°C. 
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 2.4 HUMARA assay:  
The human androgen receptor (HUMARA) assay, a polymerase chain reaction (PCR)-based 
X-chromosome inactivation assay, was used to investigate the X-chromosome inactivation 
pattern. This assay makes use of the difference in DNA methylation between active and 
inactive X-chromosome and the highly polymorphic GAC repeats in the androgen receptor 
(AR) gene. 
The HUMARA assay was performed as follows:  
2.4.1 DNA Extraction with spin column method: 
DNA extraction from cell pellets was performed using the DNeasy® Blood & Tissue Kit, 
QIGEN. 20 µl of proteinase K and 200µl of lysis buffer were added and the samples were 
incubated at 56
o
C for 10 minutes. Then 200µL of 100% ethanol was added. In order remove 
undesired components, the mixture was transferred into 2mL spin column placed in collection 
tube and centrifuged. Two washes with 500 µl of washing buffers AW1 and AW2, 
respectively, were performed. After the spin column was transferred to a microcentrifuge tube, 
100 µl of eluting buffer (AE) was added and centrifuged. The obtained DNA from each 
sample was stored at 4
o
C.  
2.4.2 DNA digestion:  
The extracted DNA from cells (hiPSC and fibroblast) was digested using the methylation 
sensitive restriction enzyme HpaII (Anza
 TM
 93 HpaII, Thermo Fisher Scientific). This enzyme 
recognizes C^CGG sites and cuts unmethylated DNA. A mix with 20µl total volume was 
prepared containing 1µL HapII, 2µL buffer (Anza 
TM
 10X buffer, Thermo Fisher Scientific) 
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and 100ng DNA. All samples were incubated at 37
o
C for 4 hours, then 1 µl HapII enzyme was 
added. The samples were left overnight at 37
o
C. In each experiment, DNA from a male sample 
was used as control for digestion, since the male X chromosome is unmethylated and these 
samples should thus be completely digested. 
2.4.3 Detection of the XCI pattern:  
To evaluate the level of inactivated X chromosomes, PCR for each DNA sample (digested and 
undigested) was performed to amplify the CAG repeat region in the first exon of the (AR) 
gene. The reaction mix, in total volume of 25 µl, consisted of: 10% 10X  AmpliTaq PCR 
buffer II, 2 mM MgCl2, 10 pmol of primers (TCCAGAATCTGTTCCAGAGCGTGC and  
GCTGTGAAGGTTGCTGTTCCTCAT), 0.2 mmol dNTP, 2.5% DMSO, 1.25 U of Amplitaq 
polymerase and 20 ng DNA.PCR conditions were as follows: 5 min at 95
o
C, followed by 35 
cycles of 30 sec at 95
o
C, 30 sec at 58
o
C, and 30 sec at 72
o
C.  Then, 7 min at 72
o
C and the 
temperature decreased to 8
o
C until the end. The PCR products were analyzed by gel 
electrophoresis and capillary electrophoresis ABI 3730 genetic analyzer (Applied Biosystems, 
Foster City, CA) using internal-lane size standard and Gene Mapper software (Applied 
Biosystems). 
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Chapter Three 
Results 
 
 
3.1 Female hiPSC lines express pluripotencey markers 
3.1.1 iPSC morphology 
In order to generate iPSC from human fibroblast, we introduced the lentiviruses containing 
Yamanaka factors into fibro ―K‖ and fibro ―S‖ (Figure 3.1-A,B). After two weeks of 
transduction, we observed small compact iPSC colonies, which resembled hES colonies 
(figure 3.2-A,B). The colonies showed clear exponential growth during the followingdays 
(Figure 3.2-C), they were flat with distinct borders in contrast to surrounding fibroblasts. 
Afterwards, we manually picked the colonies, to generate iPS cell line (figure 3.2- D,E,F). 
 
              
Figure 3.1: Microscopic images for fibroblasts obtained from two donors.A) Fibro ―K‖ and 
B)Fibro ―S‖ before transduction, scale bar: 1000 µm. 
  
A B 
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Figure 3.2: Microscopic images for iPSC lines.A&B) Micrographs of iPSC coloniesobtained ―K‖ 
(A) and ―S‖ (B) fibroblasts. Scale bar: 1000µm and 400µm , respectively.C) expanded iPSC colony 
after 20 days of transduction, scale bar: 1000µm. D) iPSC S1, one of iPSC line was generated after 
picking one of fibro ―S‖ colonies, scale bar: 200µm. E) iPSC K4, one of iPSC line generated from 
fibro ―K‖, scale bar: 1000µm. F) iPSC S4, one of iPSC line generated from fibro ―S‖, scale bar: 
1000µm. 
 
A B 
C D 
E F 
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3.1.2 Expression of surface protein markers as assessed by  immunoflurosence staining 
Since the expression of hES cell-specific surface antigens (TRA-1-60, TRA-1-81, 
SSEA3,SSEA4) is an indicator of the pluripotencey state, we performed immunoflurosence 
staining for the derived iPSC lines. All the ten iPSC lines showed positive staining for the 
pluripotency markers tested, except iPSC S3, compared to fibroblast control (Figure 3.3). 
These results indicate that we were able to successfully generate iPSC lines from the 
transformed fibroblasts. Supplementary Figure 1 displayed the fluorescence microscope 
images for the rest of iPSC lines; iPSC S4,S5,S6 derived from fibro ―S‖, and iPSC K3, K4 
derived from fibro ―K‖.   
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Figure 3.3-A: Expression of surface protein markers of fibroblast by immunoflurosence staining. 
Fluorescence microscope images for fibroblast after staining them for surface markers TRA-1-60, TRA-
1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents the 
specific staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent 
microscope (Olympus) with Cell^F software (Olympus). 
 
Figure 3.3-A: 
Fibroblast 
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Figure 3.3-B:  
Figure 3.3-B: Expression of surface protein markers of iPSC S1 by immunoflurosence staining. 
Fluorescence microscope images for iPSC S1 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color 
represents the specific staining of the intended markers. The stained cells were analyzed using the IX-81 
fluorescent microscope (Olympus) with Cell^F software (Olympus). 
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iPSC S2  
Figure 3.3-C: Expression of surface protein markers of iPSC S2 by immunoflurosence 
staining. Fluorescence microscope images for iPSC S2 after staining them for surface markers 
TRA-1-60, TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. 
Green color represents the specific staining of the intended markers. The stained cells were 
analyzed using the IX-81 fluorescent microscope (Olympus) with Cell^F software (Olympus). 
 
Figure 3.3-C :  
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Figure 3.3-D : 
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Figure 3.3-D: Expression of surface protein markers of iPSC K1 by immunoflurosence staining. 
Fluorescence microscope images for iPSC K1 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color 
represents the specific staining of the intended markers. The stained cells were analyzed using the IX-
81 fluorescent microscope (Olympus) with Cell^F software (Olympus). 
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Figure 3.3-E:  
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Figure 3.3-E: Expression of surface protein markers of iPSC K2 by immunoflurosence staining. 
Fluorescence microscope images for iPSC K2 after staining them for surface markers TRA-1-60, TRA-1-81, 
SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents the specific 
staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent microscope 
(Olympus) with Cell^F software (Olympus). 
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3.1.3 Gene expression of pluripotencey makers by RT-PCR:  
To test the pluripotency state of iPSC, we investigated the expression level of thepluripotency-
associated genes: DNMT3B, GABRB3, GDF3, LIN28, NANOG, POU5F1 and TDGF1using 
semi-quantitative PCR (RT-PCR). Analysis of cycle threshold (Ct) values of iPSC lines were 
determined and compared to their original fibroblast, fibro ―S‖ used for iPSC 
(S1,S2,S3,S4,S5,S6) and fibro‖K‖ for iPSC (K1,K2,K3,K4).Three technical replicates for 
each sample were performed to evaluate ∆Ct mean. The results show that the ∆Ct of iPSC 
lines for all the genes tested are significantly lower, compared with their original fibroblasts. 
These results indicate that we were able to successfully generate iPSC from fibroblasts (Figure 
3.4). 
 
      
  
* 
*∆Ct value of this fibroblast is arbitrarily set at 10, since no expression was observed. 
 
Figure 3.4 : 
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* 
* 
* 
* ∆Ct value of this fibroblast is arbitrarily set at 15, since no expression was observed.    
 
* ∆Ct value of this fibroblast is arbitrarily set at 15, since no expression was observed.   
 
* ∆Ct value of this fibroblast is arbitrarily set at 14, since no expression was observed.  
 
Figure 3.4: RT-PCR analysis of pluripotency marker genes. Representative figures showing the relative 
expression of the shown pluripotency genes in RNA extracted from for iPSC (K1,K2,K3,K4) derived from 
fibro ―K‖ and iPSC (S1,S2,S3,S4,S5,S6) from fibro ―S‖. Gene expression is measured as ∆Ct = Ct goi-Ct ref 
(where Ct -cycle threshold, goi – gene of interest , ref- reference gene). GUSB  and UBC were used as 
reference genes. 
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3.2 X-chromosome inactivation pattern of iPSC lines display skewing 
As DNA methylation is one of differences between active and inactive X chromosome, and 
because it plays an important role for maintenance of its inactive state, we used HUMARA 
assay to investigate the XCI patterns of derived iPSC lines.First, to make sure that the 
technique is working properly, we digested a male sample. As shown in figure 3.5-A, before 
digestion, the male showed one peak at 274 bp. After adding HapII, this peak was gone. This 
result was expected since male X chromosome is active and not methylated (figure 3.5-A). For 
fibro ―S‖, there are two peaks of the polymorphic AR locus located at 260 and 272 bp, there is 
a 12 bp (4 CTG) differences between the two X alleles (figure 3.5-B). Whereas in fibro ―K‖ 
the size of the two peaks is: 266 bp and 275 bp, the differences between the two X alleles is 9 
bp, 3 CTG repeats (figure 3.5-C). As expected in somatic cells, fibro ―S‖ and fibro ―K‖, we 
observed  random pattern of XCI from ABI capillary electrophoresis results before 
transduction (figure 3.5-B,C), since the smaller peak was disappeared after digestion and the 
second one remained in the same height.  
 Examination of the methylation status at the AR locus showed skewing in our derived iPSC 
lines from fibro ―S‖ and fibro ―K‖. In all the derived iPSC from fibro ―S‖ and fibro ―K‖ the 
smaller peak was gone after adding HapII , therefore, the first peak is unmethylated (figure 
3.5- B,C). Except in iPSC S4 the second peak was the unmethylated one. We can noting the 
skewing in the patterns from a notable change in the ratio between the two peaks after 
digestion, as one of them became higher than before digestion. Thus, this peak is methylated 
and generated from the inactive X. 
Apart from the lines that were derived specifically for this project, we also analyzed seven 
iPSC lines that were previously derived from the same fibro ―S‖ donor in the same lab. In 
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these lines, although we often observed a clear change in the ratio between the two peaks, we 
never observed a complete digestion for either one of the two peaks, which is indicative for 
random XCI (figure3.5-D).In Table 3.1, is an overview of the values of DNA methylation 
patterns for all cell lines (iPSC lines and fibroblast donors), before and after digestion. 
 
Figure 3.5-A: 
 
 
 
 
 
 
 
 
Figure 3.5-A: Methylation pattern analysis for male control cells.  Results of methylation pattern analysis 
using fragment analysis of AR loci before (HapII-)  and after (HapII+) digestion. The patterns for Male sample 
used as control for the digestion. The analysis was conducted using GeneMapper software (Applied Biosystems). 
 
A. Male control pattern: 
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Figure 3.5-B: 
 
    
 
B. Fibro “S” and iPSC “S1, S2, S3, S4, S5, S6” patterns:  
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Figure 3.5-B: Methylation pattern analysis for fibro “S” and its derived iPSC (S1,S2,S3,S4,S5, 
and S6).  Results of Methylation pattern analysis using fragment analysis of AR loci before (HapII-)  
and after (HapII+) digestion. The patterns for fibro ―S‖ and its derived iPSC (S1, S2,S3,S4,S5 and S6) 
. The analysis was conducted using GeneMapper software (Applied Biosystems). 
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Figure 3.5-C : 
 
 
   
 
C. Fibro “K” and iPSC (K1, K2,K3,K4) 
patterns:  
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Figure 3.5-C: Methylation pattern analysis for Fibro “K” and its derived iPSC (K1,K2,K3, and 
K4).  Results of Methylation pattern analysis using fragment analysis of AR loci before (HapII-)  and 
after (HapII+) digestion. The patterns for fibro ―K‖ and its derived iPSC (K1,K2,K3, and K4). The 
analysis was conducted using GeneMapper software (Applied Biosystems). 
 
Figure 3.5-D:  
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Figure 3.5-D: Methylation pattern analysis for iPSC lines derived before from fibro “S”.  Results 
of Methylation pattern analysis using fragment analysis of AR loci before (HapII-) and after (HapII+) 
digestion. The patterns for iPSC lines derived before from fibro ―S‖ for a different project.  The 
analysis was conducted using GeneMapper software (Applied Biosystems). 
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 HapII(-) HapII(+)  
Cell line  Peak 1 
fragment  
Size Peak 2 
fragment 
Size Peak 1 
fragment  
Size Peak 2 
fragment  
Size  XCI pattern 
Male control  274 12173 NA NA 274 1005 NA NA  
Fibro “S” 260 16534 272 6871 260 30439 272 32060 Random 
iPSC S1  260 32611 272 7649 260 2400 272 32397 skewing, 1st peak unmethylated 
iPSC S2 260 26433 272 3585 260 4340 272 32534 skewing, 1st peak unmethylated 
iPSC S3 260 NA 272 NA 260 <1000 272 32368 skewing, 1st peak unmethylated 
iPSC S4 260 32595 272 27606 260 >35000 272 1843 skewing,2nd peak unmethylated 
iPSC S5 260 >35000 272 13076 260 3690 272 31770 skewing, 1st peak unmethylated 
iPSC S6 260 >35000 272 10705 260 2894 272 31205 skewing, 1st peak unmethylated 
          
iS 3 260 14693 272 13915 260 26488 272 13606 doubt random/skewing 
iS 8 260 14349 272 12100 260 19921 272 6443 doubt random/skewing 
iS 9 260 16774 272 9621 260 12612 272 17625 doubt random/skewing 
iS 12 260 14687 272 13286 260 26104 272 11623 doubt random/skewing 
iS 14 260 17251 272 10072 260 10709 272 18497 doubt random/skewing 
iS 17 260 17854 272 17675 260 21408 272 9110 doubt random/skewing 
iS 22 260 32357 272 32021 260 32439 272 31025 doubt random/skewing 
          
Fibro “K” 266 27595 275 6452 266 10994 275 10818 Random 
K1 266 31509 275 8363 266 3133 275 31847 skewing, 1st peak unmethylated 
K2 266 32289 275 16070 266 2255 275 31978 skewing, 1st peak unmethylated 
K3 266 >35000 275 8172 266 3183 275 >35000 skewing, 1st peak unmethylated 
K4 266 32247 275 7906 266 3820 275 30994 skewing, 1st peak unmethylated 
D 
Table 3.1 Values of the peaks from DNA methylation patterns for the cell lines:  
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Chapter Four 
Discussion 
 
In our work, we successfully generated ten iPSC lines from fibroblasts of two healthy female 
volunteers. Characterization, and investigation of X-chromosome inactivation patterns of 
hiPSC lines was evaluated. All of the derived iPSC showed pluripotencey state by expression 
of surface protein markers (TRA-1-81, TRA-1-60, SSEA3, and SSEA4) and pluripotencey 
gene markers(DNMT3B, GABRB3, GDF3, TDGF1, LIN28, NANOG,andPOU5F1).Only S3 
did not show positive immunofluresence stainingfor specific cell surface proteins. This might 
be because the cells are partially reprogrammed, since each cell line was generated from 
heterogeneous colony that need different time to be full reprogrammed. However, repeating 
immunofluoresence staining of membrane markers at later passage and check the 
differentiation capacity into the three germ layers, will give a real indication of the 
pluripotency state of this line.  
 
The obtained lines were further used to investigate whether the XCI pattern in somatic cells 
has an influence upon iPSC reprogramming. According toDNA methyation analysis , anon-
random XCI pattern was observed in the ten derived iPSC, suggesting that all hiPSC lineswere 
derived from a single fibroblast within the donor cell population. Based on Tchieu et al, this 
clonal hiPSC occurred without reactivation of Xi and the XCI in hiPSC line reflects that of the 
starting fibroblast (Tchieu, Kuoy et al. 2010).However, we cannot exclude that X chromosome 
reactivation happened during reprogramming, followed by non random inactivation. Bruck et 
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al. describe that female hiPSC, after initial X chromosome reactivation upon derivation, 
inactivate the same X chromosome that was inactive in the parental somatic cells they were 
derived from (Bruck, Yanuka, & Benvenisty, 2013). 
 
Also, the fact that other iPSC lines that were derived before from one of the same donors 
(fibro ―S‖) showed random XCI, may be suggestive for X chromosome reactivation. However, 
in this case, it would mean that the choice for which X chromosome to inactivate after initial 
reactivation is random, and the inactivation is thus not particularly occurring to the same X 
chromosome that was inactive in the somatic cell. It is still possible thought that these 
previously obtained lines were not clonally derived and the X reactivation did not happen. 
However, all of these possibilities should be further investigated, for example, examination if 
the reactivation has occurred can be tested by comparing the XIST state in the starting 
fibroblast and its derived iPSC (using allele-specific single-cell expression analysis). 
The fact that we observed XCI skewing to the same X chromosome in our hiPSC (methylation 
of peak with size 272 in 5/6 S lines, methylation of peak with size 275 in 4/4 K lines), may 
suggest that(in)activation of a particular X chromosome confers a distinct advantage to these 
cells during cellular reprogramming or even during culture, as the passage number of the 
examined iPSC lines ranged from 3 to 7. However, in order to proof this, more experiments 
with these lines and with lines derived from other donors should be performed. An interesting 
experiment to investigate a possible culture advantage would be to perform competition 
experiments with S4 and one of the ―S‖ lines with the opposite XCI pattern.  
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In order to examine if the culture advantage is driven by chromosomal aberration, the genetic 
content of the lines should be investigated. The types of genomic abnormalities that have been 
observed in hPSC range from whole chromosome to subchromosomal aberrations, including 
gene duplications and deletions and point mutations. Advantageous duplications or deletions 
will eventually take part when certain clones thrive during derivation and expanding of hPSC 
cultures. Also, when culture conditions are changed to drive specific forms of differentiation 
(Peterson & Loring, 2014).  However, those abnormalities often confer a culture advantage 
and could confuse the hypothesis and experiments. 
 
The nonrandom pattern of X chromosome in hiPSC has a critical impact for clinical 
application and disease modeling. For studies of X-linked diseases by using female hiPSC, it 
is very important to analyze which X chromosome is expressed. Isogenic cell populations with 
the nonrandom pattern would be preferable in gene therapy, because a mosaic population of 
cells expressing the mutant and wild-type allele from the female patient can be turned into a 
pluripotent, isogenic cell population that carries the mutant allele on the Xi in all cells and thus 
solely expresses the normal form of the gene (Tchieu et al., 2010) (Pomp, Dreesen et al., 
2011). While random XCI is proposed for modeling X-linked diseasesand investigation of the 
disease phenotype. As derivation of iPSC from female with X-linked disorder could represent 
the normal cells by expressing the normal allele, and experimental mutant cells which express 
the mutant allele (Tchieu et al., 2010).  
 
Recommendations: 
For future work, more donors and iPSC lines should be examined to generalize the influence 
of X chromosome inactivation upon iPSC reprogramming. Also, it is would be helpful to 
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investigate XCI methylation related patterns for other polymorphic regions on X chromosome. 
Differentiation of iPSC lines is needed to test if the nonrandom pattern of XCI in 
undifferentiated hiPSC is maintained upon differentiation, and  if the iPSC line could be 
applied in clinical applications. Also, looking at the differentiated progeny of iPSC will give 
insight into which class of hPSC it belongs (class I, II,III ). If a mixed (random) population of 
XCIobtained after differentiation,the cells are belong to class I and reactivation occurs during 
reprogramming. The culture will shows homogenous population of X chromosome if they are 
belongs to class II or III,  after differentiation (Dandulakis, Meganathan, Kroll, Bonni, & 
Constantino, 2016).  
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SUPPLEMENTARY TABLES 
Supplementary Table 1TaqMan gene expression assays for qRT-PCR 
Gene symbol TaqMan Assay 
GABRB3 Hs00241459_m1 
TDGF1 Hs02339499_g1 
GDF3 Hs00220998_m1 
GUSB Hs99999908_m1 
DNMT3B Hs00171876_m1 
 
Supplementary Table 2The reverse, forward and the probe sequences for qRT-PCR 
Gene symbol Primer Sequence 
NANOG 
Forward 5‘-TGCAAATGTCTTCTGCTGGATG-3‘ 
Reverse 5‘-TCCTGAATAAGCAGATCCATGGA-3‘ 
Probe 6-FAM-CAGAGACTGTCTCTCCTC-MGB) 
UBC 
Forward 5‘-CGCAGCCGGATTTG-3 
Reverse 5‘-TCAAGTGACGATACAGCGA-3‘ 
Probe 6-FAM-TCGCAGTTCTTGTTTGTG-MGB 
GAPDH 
Forward 5‘-ATG GAA ATC CCA TCA CCA TCT T-3‘ 
Reverse 5‘-CGC CCC ACT TGA TTT TGG -3‘ 
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Probe 6-FAM-CAG GAG CGA GAT CC-MGB 
 
 
 
LIN28 
 
 
Forward 
 
 
5‘-CCC-CCA-GTG-GAT-GTC-TTT-GT-3‘ 
 
Reverse 
 
5‘-GCC-TCA-CCC-TCC-TTC-AAG-CT-3‘ 
 
 
Probe 
 
6-FAM-CACCAGAGTAAGCTGCACATGGAAGGG-MGB 
 
 
 
POU5F1 
 
Forward 
 
 
5‘-GGACACCTGGCTTCGGATTT-3‘ 
 
Reverse 
 
 
5‘-CATCACCTCCACCACCTGG-3‘ 
 
Probe 
 
 
6-FAM-GCCTTCTCGCCCCC-MGB 
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Supplementary Figure 1-A: Expression of surface protein markers of iPSC S5 by 
immunoflurosence staining.Fluorescence microscope images for iPSC S5 after staining them for 
surface markers TRA-1-60, TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear 
counter stain. Green color represents the specific staining of the intended markers. The stained cells 
were analyzed using the IX-81 fluorescent microscope (Olympus) with Cell^F software (Olympus). 
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B) iPSC S4 
Supplementary Figure 1-B: Expression of surface protein markers of iPSC S4 by immunoflurosence 
staining.Fluorescence microscope images for iPSC S4 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents 
the specific staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent 
microscope (Olympus) with Cell^F software (Olympus). 
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C) iPSC S6 
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Supplementary Figure 1-C: Expression of surface protein markers of iPSC S6 by immunoflurosence 
staining.Fluorescence microscope images for iPSC S6 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents 
the specific staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent 
microscope (Olympus) with Cell^F software (Olympus). 
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D) iPSC K3 
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Supplementary Figure 1-D : Expression of surface protein markers of iPSC K3 by immunoflurosence 
staining.Fluorescence microscope images for iPSC K3 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents 
the specific staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent 
microscope (Olympus) with Cell^F software (Olympus). 
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E) iPSC K4 
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Supplementary Figure 1-E : Expression of surface protein markers of iPSC K4 by immunoflurosence 
staining.Fluorescence microscope images for iPSC K4 after staining them for surface markers TRA-1-60, 
TRA-1-81,SSEA3, and SSEA4. Blue color of DAPI represent nuclear counter stain. Green color represents 
the specific staining of the intended markers. The stained cells were analyzed using the IX-81 fluorescent 
microscope (Olympus) with Cell^F software (Olympus). 
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   في الخلايا الجذعية الُمستحثة لذى الإنسان Xدراسة حالة تعطيل الكزوموسوم
 
  شذى الإيمان صوالحة : إعذاد 
  . الذكتور سيذون صلاح والذكتورة ميكا غننش: بإشزاف
 
  : الملخص
 
حٛس ذمٕو  ― ICX  ‖  أٔXذعطٛم انكشٔيٕسٕو "خلال ًَٕ ٔذطٕس انصذٚٛاخ فٙ انًشاحم انعُُٛٛح الأٔنٗ، ذًش الإَاز فٙ عًهٛح ذسًٗ 
 نًٕاصَح انفشق تٍٛ انعُٛاخ انُاظًح عًُٓا تٍٛ انعُسٍٛ، يٍ خلال إٚماف ذشظًح  نذٖ الأَُصٗ  XX  ترعطٛم أحذ انكشٔيٕسٕيٍٛ
 . انعُٛاخ انًحًٕنح عهٗ ْزا انكشيٕسٕو ٔٚرى اخرٛاس انكشيٕسٕو انًشاد ذعطٛهّ تشكم عشٕائٙ
فٙ انرطثٛماخ انعلاظٛح ٔدساسح الأيشاض عهٗ انًسرٕٖ  )sllec mets tnetopirulP(اسرخذاو انخلاٚا انعزعٛح راخ انمذسج انًرعذدج 
.  ٔذأشٛشْا عهٗ إَراض ْزِ انخلاٚاICXانًخثش٘، ٚرطهة فٓى عًهٛح 
عهٗ انخلاٚا انعزعٛح انًسرحصح  فٙ انخلاٚا انعسًٛح انًرخصصح   Xفٙ ْزِ انذساسح لًُا فٙ فحص إيكاَٛح ذأشٛش حانح انكشٔيٕسٕو
 سلالاخ يٍ انخلاٚا انعذعٛح انًسرحصح ، يٍ 01انًرٕنذج يُٓا نذٖ الإَساٌ ، حٛس لًُا تإَراض  )sllec mets tnetopirulp decudni(
 تعٕايم انُسخ الأستعح ًْا، حٛس ذى حمٍ‖K― orbiF ,‖S― orbiF(  ( لأَصٍٛ سهًٛرٍٛ )stsalborbif( خلال إعادج تشيعح خلاٚا نٛفٛح
 . عٍ طشٚك انحمٍ انفٛشٔسٙ )CYM-c dna 4FLK ,2XOS ,4TCO(
 حانح انمذسج انًرعذدج نهرخصص نذٖ ْزِ انخلاٚا يٍ خلال فحص ٔظٕد انثشٔذُٛاخ انسطحٛح انًًٛضج نهخلاٚا انًرعذدج يصم فحصٔذى 
 ).)gniniats cnecseroulfonummi  انًُاعٛح ان ًُشعحيٍ خلال عًم انصثغح ) 4AESS ,3AESS,18-1-ART , 06-1-ART(
 ,GONAN ,1FGDT ,3FDG ,3BRBAG ,B3TMND(ٔكزنك فحص إَراض ظُٛاخ ذذل عهٗ انحانح انًرعذدج نهخلاٚا يصم
  . RCP-TR(( ، تاسرخذاو ظٓاص انثهًشج انًرسهسم  82NIL ,1F5UOP(
 حًط انُٕٔ٘ٔظٕد يعًٕعح يٛصم  عهٗ ال نٓزِ انخلاٚا ٔانخلاٚا انهٛفٛح انًاَحح يٍ خلال ذحهٛم ICXإظافح إنٗ رنك ، ذى دساسح حانح 
 فٙ سلالاخ خلاٚا أخشٖ ذى إَراظٓا يٍ لثم ICX ٔكزنك ذى فحص حانح .) yassa ARAMUH(، انز٘ ذى يٍ خلال ذمُٛح )AND(
 .‖S orbiF―فٙ َفس انًخرثش يٍ إحذٖ انخلاٚا انًاَحح 
ٔلذ أظٓشخ ظًٛع انخلاٚا َرائط إٚعاتٛح نرشخٛص حانح انمذسج انًرعذدج نهرخصص، ذذل حصٕنُا عهٗ خلاٚا نٓا انمذسج انعانٛح عهٗ 
 ان ًُ عَطم  Xفٙ ْزِ انخلاٚا، فمذ أظٓشخ انُرائط ٔظٕد حانح غٛش عشٕائٛح نهكشٔيٕسٕو  Xانكشٔيٕسٕو  أيا تانُسثح نحانح. انرخصص
انًُرعح يٍ انخلاٚا انًسرحصح ، ذذل أَّ ذى إَراض أٔ ذٕنٛذ ْزِ انخلاٚا يٍ َفس انخهٛح    فٙ انعشش سلالاخ ICX modnar-non((
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ٔسٕاء .  ُيعٍٛ ٚعطٙ فائذج ذُحسٍ يٍ حٛاج تالٙ انخلاٚا خلال إعادج تشيعرٓا أٔ خلال ًَْٕا Xانهٛفٛح، ٔكزنك ٔظٕد ذأشٛش نكشٔيٕسٕو 
 انز٘ كاٌ Xحذشد عًهٛح إعادج ذفعٛم نهكشٔيٕسٕو ان ًُعطم أو نى ذحذز خلال إعادج تشيعح انخلاٚا، فإَّ ٚثذٔ أٌ َفس انكشٔيٕسٕو 
نكٍ انخلاٚا انًسرحصح الأخشٖ انرٙ ذى إَراظٓا ساتما،ً أظٓشخ َرائط يغاٚشج، حٛس . ُيعطلا ًفٙ انخهٛح الأو ذى ذعطٛهّ فٙ انخلاٚا انًسرحصح
 يًا ٚذل أَٓا لذ يشخ فٙ عًهٛح إعادج ذفعٛم نهكشٔيٕسٕو انًعطم ٔٚهٛٓا ذعطٛم  ICXُٔ ِظذ َأَٓا ذحًم ظًٛعٓا عشٕائٛح انًُٕرض 
 .عشٕائٙ نهكشٔيٕسٕو لذ لا ٚكٌٕ َفسّ انًعطم فٙ انخهٛح الأو
 عهٗ إَراض ٔتشيعح انخلاٚا انًسرحصح نكٍ يا صنُا تحاظح إنٗ عًم انًضٚذ يٍ انرعاسب  ICXفٙ انُٓاٚح، انُرائط ذُذل عهٗ ٔظٕد ذأشٛش 
 . عهٗ خلاٚا يسرحصح يخرهفح ٔيٍ عذد أكثش يٍ انًاَحٍٛ
 
 
